Clinical efficacy and pharmacokinetic profiles of intranasal and oral cetirizine in a repeated allergen challenge model of allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 4, 2007, Pages 316-321

  Korsgren, Magnus ^a   Andersson, Morgan ^a   Borgå, Olof ^b   Larsson, Lars ^c   Aldén Raboisson, Marie ^c   Malmqvist, Ulf ^a   Greiff, Lennart ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Borgå PK Consulting ^*  (Sweden)

^c Biolipox AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTIHISTAMINIC AGENT; CETIRIZINE; HISTAMINE; NLA NASAL SPRAY; NOSE SPRAY; PLACEBO; UNCLASSIFIED DRUG; ZYRLEX;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GRASS POLLEN; HUMAN; MALE; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT DURATION;

EID: 34147216577     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60876-9     Document Type: Article

References (16)

1. Davies RJ, Bagnall AC, McCabe RN, et al. Antihistamines: topical vs oral administration. Clin Exp Allergy. 1996;26(suppl 3):11-17.
2. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351:2203-2217.
3. Naclerio RM, Proud D, Kagey-Sobotka A, et al. The effect of cetirizine on early allergic response. Laryngoscope. 1989;99: 596-599.
4. Greiff L, Persson CGA, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol. 2002; 89:413-418.
5. Allocco FT, Votypka V, deTineo M, et al. Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol. 2002;89:578-584.
6. Ahlström-Emanuelsson C, Persson CGA, Svensson C, et al. Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a glucocorticosteroid. Ann Allergy Asthma Immunol. 2002;89:159-165.
7. Ahlström-Emanuelsson C, Andersson M, Persson CGA, et al. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy. 2004;34:731-735.
8. Korsgren M, Andersson M, Larsson L, et al. Onset of action of a topical antihistamine as assessed by histamine challenge-induced plasma exudation responses. Ann Allergy Asthma Immunol. 2006;96:345-348.
9. Starling-Schwanz R, Peake HL, Salome CM, et al. Repeatability of peak nasal inspiratory flow measurements and utility for assessing the severity of rhinitis. Allergy. 2005;60:795-800.
10. Greiff L, Pipkorn U, Alkner U, Persson CGA. The "nasal pool" device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin Exp Allergy. 1990;20:253-259.
11. 2-macroglobulin into human nasal airways. Clin Exp Allergy. 1997;27:438-444.
12. Svensson C, Andersson M, Greiff L, et al. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis. Allergy. 1998; 53:367-374.
13. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89:479-484.
14. Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999;36: 329-352.
15. Spencer CM, Faulds D, Peters DH, Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs. 1993;46:1055-1080.
16. Corren J, Rachelefsky G, Spector S, et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. J Allergy Clin Immunol. 1999;103: 574-580.